中文
About Us
About Us
Green Valley is an innovative Chinese pharmaceutical company that pioneers carbohydrate drugs development and manufacturing in the world.
About Green Valley
Our Business
Mission & Vision
Our Culture
Code of Business Ethics
GV-971
GV-971
Here you can get access to more information of GV-971.
Products
News Reports
Research Highlights
Milestones
Scientific Research Information
Scientific Research Information
Originality is the soul of our innovation in scientific research. We are devoted to developing drugs and healthcare solutions that patients are in the greatest need of.
Life Sciences Innovation
Research Parteners
News
News
Here you can get access to the latest news reports of Green Valley.
Press Releases
News Reports
Social Responsibility
Careers
Careers
Apart from the competitive compensation & benefits programs, we have developed a detailed benefits and perks scheme. We respect, appreciate and reward the contributions of every employee for their hard work and dedication.
Job Search
Salary and Benefits
Contact Us
Contact Us
Media Contacts
CN
News Reports

News Reports
Press Releases
News Reports
Press Releases
News Reports
Chinese answer to Alzheimer’s puzzle?
Date：2018-11-22

Evidence of an effective new treatment for Alzheimer’s would create shock waves across healthcare given the extent of the global need among millions of patients.


But it could also be a major event in geopolitics, given what making progress in this highly complex disease would say about a country’s scientific capabilities.


So it is potentially significant that a Chinese company, Green Valley Pharmaceutical, has achieved the rare feat of getting a positive read-out in a Phase III trial in mild-to-moderate Alzheimer's disease.


"GV-971 could help diversify the portfolio of treatments for this terrible disease"


Full story here: https://www.thepharmaletter.com/article/chinese-answer-to-alzheimer-s-puzzle

ShareTo：
Previous Page：
Positive Topline Results for Novel Alzheimer's Drug
Next Page：
Fits and Starts: Trial Results from the CTAD Conference